Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of TG Therapeutics Inc (NASDAQ: TGTX) was $31.11 for the day, up 2.67% from the previous closing price of $30.3. In other words, the price has increased by $2.67 from its previous closing price. On the day, 2.04 million shares were traded. TGTX stock price reached its highest trading level at $31.11 during the session, while it also had its lowest trading level at $29.92.
Ratios:
Our analysis of TGTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.89 and its Current Ratio is at 3.82. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.42.
On October 29, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $50.TD Cowen initiated its Buy rating on October 29, 2024, with a $50 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 11 ’25 when Lonial Sagar sold 20,852 shares for $32.24 per share. The transaction valued at 672,268 led to the insider holds 94,061 shares of the business.
Lonial Sagar bought 20,852 shares of TGTX for $672,233 on Sep 11 ’25. On Jun 13 ’25, another insider, Echelard Yann, who serves as the Director of the company, sold 10,000 shares for $36.94 each. As a result, the insider received 369,400 and left with 228,816 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 4939006976 and an Enterprise Value of 4671173120. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.20, and their Forward P/E ratio for the next fiscal year is 17.01. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.07. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.29 while its Price-to-Book (P/B) ratio in mrq is 7.95. Its current Enterprise Value per Revenue stands at 8.782 whereas that against EBITDA is 45.428.
Stock Price History:
The Beta on a monthly basis for TGTX is 2.02, which has changed by -0.13180518 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $25.28. The 50-Day Moving Average of the stock is -8.40%, while the 200-Day Moving Average is calculated to be -11.04%.
Shares Statistics:
TGTX traded an average of 2.03M shares per day over the past three months and 2580850 shares per day over the past ten days. A total of 155.21M shares are outstanding, with a floating share count of 143.00M. Insiders hold about 9.93% of the company’s shares, while institutions hold 63.71% stake in the company. Shares short for TGTX as of 1761868800 were 23579473 with a Short Ratio of 11.74, compared to 1759190400 on 23608291. Therefore, it implies a Short% of Shares Outstanding of 23579473 and a Short% of Float of 19.42.
Earnings Estimates
. The current market rating for TG Therapeutics Inc (TGTX) reflects the collective analysis of 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.39, with high estimates of $0.45 and low estimates of $0.34.
Analysts are recommending an EPS of between $3.09 and $2.44 for the fiscal current year, implying an average EPS of $2.89. EPS for the following year is $2.08, with 5.0 analysts recommending between $2.56 and $1.79.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $187.66M to a low estimate of $176.9M. As of. The current estimate, TG Therapeutics Inc’s year-ago sales were $108.19MFor the next quarter, 7 analysts are estimating revenue of $195.39M. There is a high estimate of $209.5M for the next quarter, whereas the lowest estimate is $187.3M.
A total of 7 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $611.38M, while the lowest revenue estimate was $600.6M, resulting in an average revenue estimate of $605.03M. In the same quarter a year ago, actual revenue was $329MBased on 8 analysts’ estimates, the company’s revenue will be $901M in the next fiscal year. The high estimate is $955.86M and the low estimate is $847.5M.
